Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03154996 · ClinicalTrials.gov registry record · Phase 1
Chronic Convection Enhanced Delivery of Topotecan
A Phase 1 study, sponsored by Columbia University.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT03154996 is a Phase 1 study that has completed, run by Columbia University. The registered enrollment target is 5 participants.
The verdict
NCT03154996, a Phase 1 study, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
The primary goal of this study is to establish, for the first time, safety of prolonged intracerebral convection enhanced delivery of chemotherapy in patients with recurrent high grade glioma (HGG). Secondary objectives will include determination of topotecan (TPT) distribution and radiographic tumor response with prolonged continuous intracerebral convection-enhanced delivery (CED).
Interventions
- DRUG Topotecan
- DRUG Gadolinium
- DEVICE Synchromed II infusion pumps
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2018-01-18 |
| Est. Completion | 2021-08-20 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03154996
The ClinicalTrials.gov registry entry for NCT03154996 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Topotecan is the first listed.
NCT03154996 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03154996 about?
NCT03154996 is a clinical study titled "Chronic Convection Enhanced Delivery of Topotecan". The primary goal of this study is to establish, for the first time, safety of prolonged intracerebral convection enhanced delivery of chemotherapy in patients with recurrent high grade glioma (HGG). Secondary objectives will include determination of topotecan (TPT) distribution and radiographic tumo...
What is the current status of trial NCT03154996?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2018-01-18. Estimated completion is 2021-08-20.
What interventions are being tested in trial NCT03154996?
The interventions under investigation include: Topotecan (DRUG), Gadolinium (DRUG), Synchromed II infusion pumps (DEVICE).
Who is sponsoring clinical trial NCT03154996?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.